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Dr Jonathan Broomberg, 
CEO of Discovery Health, 
and Milton Streak, the 
Principal Officer of the 
Discovery Health Medical 
Scheme, said both entities supported the 
Council for Medical Schemes (CMS) and 
did not agree with the Board of Healthcare 
Funders (BHF) in its view on Regulation 8. 
Discovery Health Medical Scheme and 
other schemes managed by Discovery 
Health had ‘for several years, had payment 
arrangements in place allowing members’ 
access to full payment for PMB [Prescribed 
Member Benefit] conditions’. 
Broomberg painted a broader picture of 
healthcare inflation, saying it was due to 
a number of interacting factors including 
tariffs and other supply-side factors, as 
well as powerful demand-side factors that 
continuously drove up the usage of health 
services. ‘Tariffs paid to doctors and hospitals 
increase at or just above CPI [consumer price 
index] levels on an annual basis. However, 
each year, the usage of healthcare services by 
scheme members increases by 3 - 4% due to 
the combination of ageing, higher chronic 
disease prevalence as well as new medicines 
and medical technology that often come 
onto the market at significantly higher costs 
than the medicines they replace. Thus, both 
tariffs and utilisation contribute to medical 
inflation, but our data show that utilisation 
is the more significant of these over the past 
several years.’ 
Cancer costs doubled in 
last 3 years – Broomberg
These trends were clearly shown by the 
costs of treating cancer. Total oncology 
spend for Discovery Health Medical 
Scheme increased by 17% from 2010 to 
2011 (R872 million to R1.02 billion). The 
combination of higher treatment costs 
and higher rates of cancer incidence had 
doubled the costs of cancer treatments 
in the Discovery Health Medical Scheme 
over the past 3 years. Broomberg explained 
that the underlying market dynamics also 
contributed to healthcare inflation, with a 
‘serious and growing shortage of specialists, 
and some areas of market concentration 
in the supply of various services’. More 
important than tariffs, however, were two 
fundamental features of the country’s private 
healthcare delivery system – the fee for 
service payment system, and the fragmented 
structure in which doctors, hospitals and all 
other providers worked in silos with ‘almost 
no coordination between them’. 
‘Our healthcare system needs to work to 
reduce waste and inefficiency at all levels. 
On the supply side, we need concerted action 
from funders, hospital groups and doctors to 
examine and work together on alternatives to 
fee-for-service, for example payment models 
that better align incentives for efficiency, 
and quality of care. Equally important is 
to move away from uncoordinated and 
fragmented healthcare delivery systems, 
towards integrated healthcare teams. None 
of this can be imposed by funders, however. 
These shifts must be led by the doctors 
and other health professionals working 
with medical schemes. We also need a shift 
away from general private hospitals towards 
more efficient hospital delivery models, 
including high-volume day surgery centres 
and specialised units using lean production 
approaches. More coordination between 
different healthcare providers and sharing 
of critical and vital medical information 
are critical elements to ensure efficiency in 
our healthcare system. On the demand side, 
medical schemes and employers must invest 
more in wellness approaches that address the 
burden of chronic diseases of lifestyle.’
‘Adverse selection’ a 
major inflation driver
In addition, South Africa’s private healthcare 
system faced some ‘unique’ demand-side 
challenges, which added fuel to the inflation 
fire. ‘Our medical scheme legislation 
is laudably egalitarian; it is based on open 
enrolment and community rating – medical 
schemes must accept all applicants regardless 
of age and health status – and schemes must 
charge the same premium for all members 
in each option, regardless of health status or 
age. While these laws are common in many 
global health insurance systems, and highly 
effective in protecting individuals against 
discrimination based on their health risks, 
they are almost universally implemented in 
conjunction with a legal mandate for all eligible 
individuals to take out health insurance. 
Only South Africa enforces open enrolment 
and community rating, but allows scheme 
membership to remain voluntary. This 
unbalanced arrangement leads to a significant 
problem of “adverse selection” against medical 
schemes – the young and healthy join a scheme 
only when they believe they will really need 
healthcare, and new joiners typically join lower 
benefit options, and “buy up” to higher plans 
only if they become ill.’ 
These factors contributed significantly to 
healthcare inflation by driving high annual 
increases in the usage of services by the 
average scheme member, while medical 
schemes increasingly lost out on the surplus 
funds generated by the young and healthy 
– which they ‘desperately needed’ to fund 
the higher claims of the elderly and the 




S Afr Med J 2013;103(12):887.  
DOI:10.7196/SAMJ.7692
Discovery Health’s take on Regulation 8
Dr Jonathan Broomberg, CEO of Discovery 
Health. 
‘Both tariffs and utilisation 
contribute to medical inflation, 
but our data shows that 
utilisation is the more significant 
of these over the past several 
years.’ – Jonathan Broomberg
